At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

In addition to his positions at Prometheus and Abbvie, Mr. Stenhouse held an executive leadership ... enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with ...

David Risinger’s rating is based on several key considerations surrounding AbbVie’s recent clinical trial outcomes. The company’s announcement on November 11, 2024, revealed that emraclidine’s Phase 2 ...

BeiGene may lose the lawsuit to AbbVie over Brukinsa and start to pay royalties ... We think it is sensible if BeiGene plans to pursue tens of molecule targets with multiregional clinical trials at ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

"AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trials" was originally created and published by ...

JS and TV are supported by a senior clinical researcher fellowship from the Research Foundation Flanders (FWO). Competing ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...